UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Peptidomimetics - A Versatile Route to Biologically Active Compounds

European Journal of Organic Chemistry, 2009-10, Vol.2009 (30), p.5099-5111

2009

Volltextzugriff (PDF)

One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study

Journal of bone and mineral research, 2019-03, Vol.34 (3), p.419-428

2019

Volltextzugriff (PDF)

Do odour impact criteria of different jurisdictions ensure analogous separation distances for an equivalent level of protection?

Journal of environmental management, 2019-06, Vol.240, p.394-403

2019

Volltextzugriff (PDF)

Role of RANK Ligand and Denosumab, a Targeted RANK Ligand Inhibitor, in Bone Health and Osteoporosis: A Review of Preclinical and Clinical Data

Clinical therapeutics, 2012-03, Vol.34 (3), p.521-536

2012

Volltextzugriff (PDF)

Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial

Journal of bone and mineral metabolism, 2020-05, Vol.38 (3), p.310-315

2020

Volltextzugriff (PDF)

Citizen science based monitoring of Greylag goose (Anser anser) in Bavaria (Germany): combining count data and bag data to estimate long-term trends between 1988/89 and 2010/11

PloS one, 2015-06, Vol.10 (6), p.e0130159-e0130159

2015

Volltextzugriff (PDF)

Effects of denosumab on bone turnover markers in postmenopausal osteoporosis

Journal of bone and mineral research, 2011-03, Vol.26 (3), p.530-537

2011

Volltextzugriff (PDF)

Healthcare Policy Changes in Osteoporosis Can Improve Outcomes and Reduce Costs in the United States

JBMR plus, 2019-09, Vol.3 (9), p.e10192-n/a

2019

Volltextzugriff (PDF)

Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial

Journal of bone and mineral research, 2013-04, Vol.28 (4), p.746-752

2013

Volltextzugriff (PDF)

Underdiagnosis of Vertebral Fractures Is a Worldwide Problem: The IMPACT Study

Journal of bone and mineral research, 2005-04, Vol.20 (4), p.557-563

2005

Volltextzugriff (PDF)

Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension

Archives of osteoporosis, 2019-06, Vol.14 (1), p.59-59, Article 59

2019

Volltextzugriff (PDF)

Bone remodeling in postmenopausal women who discontinued denosumab treatment: Off‐treatment biopsy study

Journal of bone and mineral research, 2011-11, Vol.26 (11), p.2737-2744

2011

Volltextzugriff (PDF)

Characterization of Year-to-Year Variability of Separation Distances Between Odour Sources and Residential Areas to Avoid Annoyance

Chemical engineering transactions, 2018-10, Vol.68

2018

Volltextzugriff (PDF)

The Effect of 1 Year of Romosozumab on the Incidence of Clinical Vertebral Fractures in Postmenopausal Women With Osteoporosis: Results From the FRAME Study

JBMR plus, 2019-10, Vol.3 (10), p.e10211-n/a

2019

Volltextzugriff (PDF)

Stable Right- and Left-Handed Peptide Helices containing Cα-Tetrasubstituted α-Amino Acids

Journal of organic chemistry, 2009-05, Vol.74 (10), p.3718-3726

2009

Volltextzugriff (PDF)

Validation of the Osteoporosis-Specific Morisky Medication Adherence Scale in long-term users of bisphosphonates

Quality of life research, 2014-09, Vol.23 (7), p.2109-2120

2014

Volltextzugriff (PDF)

Stable right- and left-handed peptide helices containing C(alpha)-tetrasubstituted alpha-amino acids

Journal of organic chemistry, 2009-05, Vol.74 (10), p.3718-3726

2009

Volltextzugriff (PDF)

Denosumab for treatment of postmenopausal osteoporosis

American journal of health-system pharmacy, 2011-08, Vol.68 (15), p.1409-1418

2011

Volltextzugriff (PDF)

Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis

The New England journal of medicine, 2017-10, Vol.377 (15), p.1417-1427

2017

Volltextzugriff (PDF)

Synthesis of new C α -tetrasubstituted α-amino acids

Beilstein journal of organic chemistry, 2009-02, Vol.5 (1), p.5

2009

Volltextzugriff (PDF)

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

The New England journal of medicine, 2016-10, Vol.375 (16), p.1532-1543

2016

Volltextzugriff (PDF)

Change in Bone Density and Reduction in Fracture Risk: A Meta‐Regression of Published Trials

Journal of bone and mineral research, 2019-04, Vol.34 (4), p.632-642

2019

Volltextzugriff (PDF)

Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study

Bone (New York, N.Y.), 2017-10, Vol.103, p.209-215

2017

Volltextzugriff (PDF)

Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial

The Lancet (British edition), 2017-09, Vol.390 (10102), p.1585-1594

2017

Volltextzugriff (PDF)

Romosozumab in Postmenopausal Women with Low Bone Mineral Density

The New England journal of medicine, 2014-01, Vol.370 (5), p.412-420

2014

Volltextzugriff (PDF)

1 – 25 von 179

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(141)
Mit Volltextzugriff
(156)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(105)
Life Sciences & Biomedicine
(90)
Humans
(71)
Female
(45)
Osteoporosis
(33)
Endocrinology & Metabolism
(32)
Aged
(31)
Middle Aged
(29)
Biological And Medical Sciences
(24)
Aged, 80 And Over
(20)
Bone Density
(20)
Male
(20)
Bone Mineral Density
(16)
Osteoporosis, Postmenopausal - Drug Therapy
(16)
Post-Menopause
(15)
Adult
(14)
Bone Density Conservation Agents - Therapeutic Use
(14)
Fractures
(14)
Medical Sciences
(14)
Monoclonal Antibodies
(14)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Peptidomimetics - A Versatile Route to Biologically Active Compounds

One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study

Do odour impact criteria of different jurisdictions ensure analogous separation distances for an equivalent level of protection?

Role of RANK Ligand and Denosumab, a Targeted RANK Ligand Inhibitor, in Bone Health and Osteoporosis: A Review of Preclinical and Clinical Data

Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial

Citizen science based monitoring of Greylag goose (Anser anser) in Bavaria (Germany): combining count data and bag data to estimate long-term trends between 1988/89 and 2010/11

Effects of denosumab on bone turnover markers in postmenopausal osteoporosis

Healthcare Policy Changes in Osteoporosis Can Improve Outcomes and Reduce Costs in the United States

Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial

Underdiagnosis of Vertebral Fractures Is a Worldwide Problem: The IMPACT Study

Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension

Bone remodeling in postmenopausal women who discontinued denosumab treatment: Off‐treatment biopsy study

Characterization of Year-to-Year Variability of Separation Distances Between Odour Sources and Residential Areas to Avoid Annoyance

The Effect of 1 Year of Romosozumab on the Incidence of Clinical Vertebral Fractures in Postmenopausal Women With Osteoporosis: Results From the FRAME Study

Stable Right- and Left-Handed Peptide Helices containing Cα-Tetrasubstituted α-Amino Acids

Validation of the Osteoporosis-Specific Morisky Medication Adherence Scale in long-term users of bisphosphonates

Stable right- and left-handed peptide helices containing C(alpha)-tetrasubstituted alpha-amino acids

Denosumab for treatment of postmenopausal osteoporosis

Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis

Synthesis of new C α -tetrasubstituted α-amino acids

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

Change in Bone Density and Reduction in Fracture Risk: A Meta‐Regression of Published Trials

Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study

Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial

Romosozumab in Postmenopausal Women with Low Bone Mineral Density

Suchergebnisse filtern